Research Article
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus
NPH Insulin during Pregnancy
Table 2
Baseline maternal characteristics of pregnant women using insulin glargine versus NPH among the studies selected for meta-analysis.
| Maternal
characteristic | Number of studies | Insulin glargine | NPH | Mean
difference* | 95% confidence limits | | Unadjusted mean/events | Number of
Patients | Unadjusted mean/events | Number of
Patients | Lower limit | Upper limit |
| | Maternal age (yrs) | 7 | 30.3 | 289 | 30.5 | 322 | −0.49 | −1.87 | 0.89 | | Duration of diabetes (yrs) | 7 | 10.2 | 250 | 10.3 | 278 | 1.14 | 0.28 | 2.00 | | Type 1 diabetes | 5 | 15.4 | 117 | 14.6 | 133 | 1.67 | 0.82 | 2.52 | | Pregestational diabetes | 3 | 6.1 | 140 | 6.4 | 146 | 0.69 | −0.96 | 2.35 | | Prepregnancy weight (kg) | 4 | 82.0 | 154 | 80.1 | 190 | 1.53 | −2.21 | 5.27 | | Prepregnancy BMI (kg/m2) | 3 | 31.0 | 140 | 29.7 | 139 | −0.46 | −1.81 | 0.90 |
|
|
*Mean difference: insulin glargine versus NPH insulin.
|
